Cargando…

Can Histological Grade and Mitotic Index Replace Ki67 to Determine Luminal Breast Cancer Subtypes?

INTRODUCTION: Breast cancer can be classified into subtypes based on immunohistochemical markers, with Ki67 expression levels being used to divide luminal BC tumors in luminal A and B subtypes; however, Ki67 is not routinely determined due to a lack of standardization. OBJECTIVE: To evaluate histolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oddó, David, Pulgar, Dahiana, Elgueta, Nicole, Acevedo, Francisco, Razmiliz, Dravna, Navarro, María Elena, Camus, Mauricio, Merino, Tomás, Retamal, Ignacio, Pérez-Sepúlveda, Alejandra, Villarroel, Alejandra, Galindo, Héctor, Peña, José, Sánchez, César
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844615/ https://www.ncbi.nlm.nih.gov/pubmed/29373911 http://dx.doi.org/10.22034/APJCP.2018.19.1.179

Ejemplares similares

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer
por: Rivas, Mauricio, et al.
Publicado: (2019)

Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence
por: Sánchez, Cesar, et al.
Publicado: (2016)

Breast papillary lesions: an analysis of 70 cases
por: Boin, Dahiana Pulgar, et al.
Publicado: (2014)

Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution
por: Maiz, Cristóbal, et al.
Publicado: (2020)

Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early‐stage luminal breast cancer
por: van Steenhoven, Julia E C, et al.
Publicado: (2020)

Ki-67 acts as a biological surfactant to disperse mitotic chromosomes
por: Cuylen, Sara, et al.
Publicado: (2016)

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes
por: Viale, Giuseppe, et al.
Publicado: (2019)

Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer
por: YUAN, PENG, et al.
Publicado: (2016)

MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers
por: Sadeghian, Dorsay, et al.
Publicado: (2022)

Lung carcinoid tumours: histology and Ki‐67, the eternal rivalry
por: Centonze, Giovanni, et al.
Publicado: (2022)

Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years
por: Carrillo, Mitzy, et al.
Publicado: (2019)

Ki-67 is a PP1-interacting protein that organises the mitotic chromosome periphery
por: Booth, Daniel G, et al.
Publicado: (2014)

Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors
por: KEMMERLING, RALF, et al.
Publicado: (2014)

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
por: Cheang, Maggie C. U., et al.
Publicado: (2009)

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
por: Ciruelos, E, et al.
Publicado: (2011)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results
por: Noske, Aurelia, et al.
Publicado: (2019)

Combined Use of cyclinD1 and Ki67 for Prognosis of Luminal-Like Breast Cancer Patients
por: Hao, Junmei, et al.
Publicado: (2021)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

The Ki-67 and RepoMan mitotic phosphatases assemble via an identical, yet novel mechanism
por: Kumar, Ganesan Senthil, et al.
Publicado: (2016)

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
por: Inic, Zorka, et al.
Publicado: (2014)

Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods
por: Lashen, Ayat, et al.
Publicado: (2022)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas
por: Duregon, Eleonora, et al.
Publicado: (2016)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method
por: Jang, Min Hye, et al.
Publicado: (2017)

Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
por: Silva, Leonardo Roberto da, et al.
Publicado: (2019)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Prognostic impact of Ki-67 in patients with gastric cancer—the importance of depth of invasion and histologic differentiation
por: Ko, Gyung Hyuck, et al.
Publicado: (2017)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
por: Jacquemier, Jocelyne, et al.
Publicado: (2009)

Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer
por: Ushimado, Kaori, et al.
Publicado: (2019)

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy
por: Tan, Shirong, et al.
Publicado: (2021)

Validation of absolutely quantitated Ki67 and cyclinD1 protein levels for prognosis of Luminal‐like breast cancer patients
por: Yu, Guohua, et al.
Publicado: (2022)

Clinicopathologic subtypes and compromise of lymph nodes in patients with breast cancer
por: Jaime Jans, B, et al.
Publicado: (2014)

Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer
por: Aziz, Sura, et al.
Publicado: (2016)

The p150N domain of chromatin assembly factor-1 regulates Ki-67 accumulation on the mitotic perichromosomal layer
por: Matheson, Timothy D., et al.
Publicado: (2017)

Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma
por: Rossi, L, et al.
Publicado: (2015)

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

Unravelling actionable biology using transcriptomic data to integrate mitotic index and Ki-67 in the management of lung neuroendocrine tumors
por: Manem, Venkata S.K., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_erv0emnobpm4o058egbnd6tgnk